Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL
Abstract
TO THE EDITOR:
The anti-CD20 monoclonal antibody rituximab, together with anthracycline, in hepatitis B surface antigen (HBsAg) healthy carriers affected by non-Hodgkin lymphoma (NHL) increases hepatitis B virus (HBV) reactivation risk.[1][1] Oral primary antiviral prophylaxis (PAVP) is a...
Paper Details
Title
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL
Published Date
Jan 31, 2019
Journal
Volume
133
Issue
5
Pages
498 - 501
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History